Study of drug delivery through metallic nanoparticles in

therapeutics of Ocular melanoma

Sidra Batool Malik

Supervisor
Dr. Asma Gul
Associate Professor
Co Supervior
Dr.Khurrum Mehbob
 Introduction
 Cancer that starts in the eye is called intraocular cancers (Hopp et
al., 2006).

 Melanoma is the most common cancer in the eye

 Most eye cancer develops in the uvea (Harbour et al., 2006).

 Lymphoma is the second most common form of eye cancer

(Hopp et al., 2006 ).
 Prevalence
.
 Uveal melanoma has the highest rate of metastasis, with a 40% metastasis rate
(median survival 2–7 months) and about 50% of mortal cases due to
metastasis.(Elshaw et al, 2011).

 A survey from the 39 countries estimated that 285 million people suffer from visual
impairments, of these 65% are above 50 and 82% of blind patients above 45
(Pascolini et al, 2011).
 Causes And Risk Factors
 Sun exposure
 Certain occupations
 Welders
 Farmers
 Fishermen
 Chemical workers
 Laundry Workers
 Secondary causes
 Scientists are currently researching DNA to understand the causes
Age, ethnicity and eye color ( Finger et al., 2010).
 Ocular Tumors
 Kim et al, 2010

Cancerous

Melanoma Lymphoma Retinoblastoma

Iris melanoma

Cilliary
Uveal melanoma
melanoma
Choroid
melanoma
 Symptoms

 A growing dark spot on the iris.

 A sensation of flashing lights.
 A change in the shape of pupil at the center of your eye.
 Poor or blurry vision in one eye.
 Loss of peripheral vision.
Sensation of flashes and specks of dust in your vision.
(Vang et al., 2009).
Where eye melanoma occurs?
Kim et al, 2010
 Treatments
Based on location and size
Surgery
Radiation
Laser
Chemotherapy

(Vang et al., 2009).

 Nanoparticles In Ocular cancers Treatment

 Most nanodevices are in nanoparticle form with different sizes ranging from 10
nm–1000 nm (Januria et al., 2007).

 Nanoparticles made from chitosan have been used for topical drug administration
and found to possess good ocular biocompatibility (de campos et al,2004).

 Intravitreally injected albumin nanoparticles have also been shown to accumulate in

the vitreous and ciliary body (Merodio et al., 2002).

 These FDA approved polymers have very good biocompatibility and have shown
impressive drug delivery capabilities in both the anterior and posterior chamber
(Vega et al., 2006).
 Objectives
 The objectives of my study are:

 Synthesis of metallic nanoparticles.

 Characterization of metallic nanoparticles.
 Conjugation of anticancer drug with nanoparticles.
 Application of drug loaded nanoparticles on OM cell lines.
 Materials and Methods

Characterization of
NPs through
Synthesis of various Conjugation with
nanoparticles: techniques: drug:
Chemical Method TEM Cisplatin etc.
SEM
FTIR

Culturing and sub

in vitro culturing of cancer
Data analysis
analysis cell lines
MEL 202
Possible future outcomes

Targeting eye tumors with less side effects by utilizing metallic

nanoparticles as a drug carrier agents.
 References
 Hoppe E, Frankel R. Optometrists as key providers in the prevention and early detection of
malignancies. Optometry 2006.
 Harbour JW. Eye cancer: unique insights into oncogenesis: the Cogan Lecture. Invest Ophthalmol Vis
Sci 2006.
 Elshaw SR, Sisley K, Cross N, Murray AK, MacNeil SM, Wagner M, Nichols CE, Rennie IG. A
comparison of ocular melanocyte and uveal melanoma cell invasion and the implication of alpha1beta1,
alpha4beta1 and alpha6beta1 integrins. Br J Ophthalmol 2001.
 Pascolin D, Mariotti SP. Global estimates of visual impairment:2010. Br .J Opthamol 2011.
 Finger, P. (n.d.). Eye Cancer. Doctor-approved cancer information from ASCO | Cancer.Net. Retrieved
July 17, 2010.
 Vang, C. (2009, February 13). UW Eye Research Institute. UW Eye Research Institute-Point of View,
Fall 2007. Retrieved July 17, 2010.
 Janoria KG, Gunda S, Boddu SHS, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin
Drug Deliv 2007.
 Vega, Egea MA, Valls O, Espina M, Garcia ML. Flurbiprofen loaded biodegradable nanoparticles for
ophthalmic administration. J Pharm Sci 2006.
 de Campos M, Diebold Y, Carvalho EL, Sanchez A, Alonso MJ. Chitosan nanoparticles as new ocular
drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res 2004.
 Merodio M, Irache JM, Valamanesh F, Mirshahi M. Ocular disposition and tolerance of ganciclovir-
loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 2002.
 References
 Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of
metastatic uveal melanoma. Arch Ophthalmol. 2010;128:871–5.